rogocekib development for expanded indications in ovarian cancer and MDS

An individual drug development theme for rogocekib, prioritizing AML as the lead indication while expanding development into ovarian cancer and myelodysplastic syndrome (MDS).

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2025 →Last written FY2025

Directionhelps1 helps · 0 hurts · 0 flat

Loading